Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
54 hedge funds and large institutions have $7.86M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 10 closing their positions.
7% less funds holding
Funds holding: 58 → 54 (-4)
16% less capital invested
Capital invested by funds: $9.31M → $7.86M (-$1.44M)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$330K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$314K |
| 3 |
BC
BIT Capital
Berlin,
Germany
|
+$223K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$124K |
| 5 |
CWA
CM Wealth Advisors
Beachwood,
Ohio
|
+$54.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$99.1K |
| 2 |
Two Sigma Investments
New York
|
-$92.1K |
| 3 |
Two Sigma Advisers
New York
|
-$84K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$55.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$54.4K |
ONCT Hedge Fund Activity: Q1 2023 in Review
54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2023, worth a combined $7.86M — down 16% from $9.31M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ONCT and 6 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $330K. The largest seller was BlackRock, cutting an estimated $99.1K.
- 54 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2023, down from 58 in Q4 2022.
- Funds reported $7.86M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2023, down 16% quarter-over-quarter.
- 6 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -4 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2023 was Millennium Management, an estimated $330K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2023 was BlackRock, an estimated $99.1K sold.
Based on aggregated 13F filings for Q1 2023.